Form D · Biotechnology
Surrozen, Inc.
South San Francisco, CA · CIK 0001814550
Offering snapshot reported Jun 23, 2020 · SEC filing
- Reported sold
- $50M Offering amount: $50M
- Investors reported
- 12 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 4, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 23, 2020 | Initial | $49,999,991 | No comparison | 12 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-369446
Source: Form D, filed Jun 23, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Anna Berkenblit | Director |
| David Goeddel | Director |
| Tim Kutzkey | Director |
| Craig Parker | Director, Executive |
| Harold Varmus | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
171 Oyster Point Blvd. Suite 400
South San Francisco, CA, 94080
South San Francisco, CA, 94080